The House of Representatives voted this week to extend a Department of Defense psychedelics research program by six years and to write parts of a Trump-era psychedelics executive order into federal law, folding both measures into the Fiscal Year 2027 National Defense Authorization Act. The same chamber, however, refused to let a separate cannabis-related proposal - one that would have pushed the Air Force, Space Force and Marine Corps to expand enlistment waivers for recruits who tested positive for THC - even reach the floor for a vote. The split outcome says something worth sitting with: psychedelics research tied to veteran mental health is gaining bipartisan traction in Congress, while cannabis policy inside the military bureaucracy remains stuck in place.
For operators watching from the cannabis retail side, none of this changes state-level compliance obligations, but it does underline how federal drug policy keeps moving in fragmented, sometimes contradictory directions - a dynamic that dispensary owners already navigate daily through seed-to-sale tracking, METRC reporting and shifting banking rules. Multi-state operators building out new markets know that regulatory whiplash isn't limited to Washington; it shows up in state licensing timelines, in local zoning fights, and in the point-of-sale infrastructure retailers depend on to stay audit-ready. In Missouri, for instance, retailers managing compliant inventory across adult-use and medical channels increasingly rely on POS software for Missouri cannabis retailers to keep transaction records, tax reporting and product batch data aligned with state requirements - the kind of back-office discipline that federal inaction on cannabis makes even more necessary, not less. POS software for Missouri cannabis retailers
What the NDAA Amendments Actually Do
The psychedelics provisions extend DOD's existing clinical trial authority - first established under the 2024 NDAA - for active-duty service members with PTSD or traumatic brain injury, pushing the research window out to September 30, 2033, and requiring annual progress reports for nine years instead of three. A second amendment would codify pieces of Trump's April executive order, directing the Department of Veterans Affairs to name an official overseeing "emerging therapeutic interventions" and to report back to Congress on ibogaine and related research within set deadlines. None of this authorizes psychedelics use outside controlled clinical settings, and none of it changes DEA scheduling. It's a research and reporting framework, not a legalization pathway - a distinction that matters for anyone trying to gauge how fast federal policy might actually shift.
Why the Cannabis Waiver Amendment Stalled
The blocked amendment, from Reps. Dave Joyce and Dina Titus, would have required the Air Force, Space Force and Marine Corps to adopt waiver systems similar to what the Army and Navy already use for recruits with prior positive THC tests. The House Rules Committee simply declined to let it advance - no floor debate, no vote. That's a procedural dead end, not a policy defeat on the merits, but the practical effect is the same: recruits who fail a cannabis toxicology screen in three of five military branches still face rejection with no formal path to reapply. Meanwhile, DOD reaffirmed this month that marijuana use remains prohibited for service members and civilian employees regardless of state legalization or the federal rescheduling process underway. For an industry that's spent years arguing cannabis stigma is fading, the military's continued zero-tolerance posture - extending even to hemp-derived CBD products and hair care items - is a reminder that federal institutions move on their own schedule, largely untouched by state-level normalization.
The Bigger Picture for Cannabis Businesses
None of this legislation touches state-licensed dispensary operations directly. But it does illustrate a pattern operators should track closely: Congress is comfortable expanding research access for psychedelics tied to veteran health narratives, while cannabis-specific reforms - waiver expansion, banking access, rescheduling follow-through - keep stalling in committee or getting stripped out during conference negotiations, as happened with a similar cannabis testing amendment in 2024. That inconsistency has real consequences for compliance planning, wholesale relationships and long-term investment decisions in a sector still operating under 280E tax burdens and inconsistent banking access. Retailers and suppliers watching Washington for signals on federal cannabis reform should treat this NDAA cycle as further evidence that meaningful change, if it comes, will likely arrive piecemeal and slowly - not through a single sweeping bill.
